TY - JOUR
T1 - Transmitted antiretroviral drug resistance in newly HIV-Infected and untreated patients in ségou and bamako, mali
AU - Maiga, Almoustapha Issiaka
AU - Fofana, Djeneba Bocar
AU - Maiga, Aichatou Chehy
AU - Diallo, Fodie
AU - Ait-Arkoub, Zaina
AU - Daou, Fatoumata
AU - Cisse, Mamadou
AU - Sarro, Yaya Dit Sadio
AU - Oumar, Aboubacar Alassane
AU - Sylla, Aliou
AU - Katlama, Christine
AU - Taiwo, Babafemi
AU - Murphy, Robert
AU - Tounkara, Anatole
AU - Marcelin, Anne Genevieve
AU - Calvez, Vincent
N1 - Copyright:
Copyright 2013 Elsevier B.V., All rights reserved.
PY - 2013/1/1
Y1 - 2013/1/1
N2 - The WHO recommends regular surveillance for transmitted antiretroviral drug-resistant viruses in HIV antiretroviral treatment (ART)-naive patients in resource-limited settings. This study aimed to assess the prevalence of mutations associated with resistance in ART-naive patients newly diagnosed with HIV in Bamako and Ségou in Mali. HIV-positive patients who never received ART were recruited in Bamako and Ségou, Mali. The reverse transcriptase (RT) and protease (PR) genes of these patients were sequenced by the "ViroSeq" method. Analysis and interpretation of the resistance were made according to the WHO 2009 list of drug resistance mutations. In all, 51/54 (94.4%) sample patients were sequenced. The median age (IQR) of our patients was 24 (22-27) years and the median CD4 count was 380 (340-456) cells/mm 3. The predominant subtype was recombinant HIV-1 CRF02-AG (66.7%) followed by CRF06-cpx (12%) and CRF09-cpx (4%). Four patients had mutations associated with resistance, giving an overall prevalence of resistance estimated at 7.9%. There were two (4%) patients with nucleoside reverse transcriptase inhibitor (NRTI) mutations (one M184V and one T215Y), two (4%) with non-NRTI mutations (two K103N), and one (2%) with a protease inhibitor mutation (one I54V). The prevalence of primary resistance in newly infected patients in Mali is moderate (7.9%). This indicates that the standard NNRTI-based first-line regimen used in Mali is suboptimal for some patients. This study should be done regularly to inform clinical practice.
AB - The WHO recommends regular surveillance for transmitted antiretroviral drug-resistant viruses in HIV antiretroviral treatment (ART)-naive patients in resource-limited settings. This study aimed to assess the prevalence of mutations associated with resistance in ART-naive patients newly diagnosed with HIV in Bamako and Ségou in Mali. HIV-positive patients who never received ART were recruited in Bamako and Ségou, Mali. The reverse transcriptase (RT) and protease (PR) genes of these patients were sequenced by the "ViroSeq" method. Analysis and interpretation of the resistance were made according to the WHO 2009 list of drug resistance mutations. In all, 51/54 (94.4%) sample patients were sequenced. The median age (IQR) of our patients was 24 (22-27) years and the median CD4 count was 380 (340-456) cells/mm 3. The predominant subtype was recombinant HIV-1 CRF02-AG (66.7%) followed by CRF06-cpx (12%) and CRF09-cpx (4%). Four patients had mutations associated with resistance, giving an overall prevalence of resistance estimated at 7.9%. There were two (4%) patients with nucleoside reverse transcriptase inhibitor (NRTI) mutations (one M184V and one T215Y), two (4%) with non-NRTI mutations (two K103N), and one (2%) with a protease inhibitor mutation (one I54V). The prevalence of primary resistance in newly infected patients in Mali is moderate (7.9%). This indicates that the standard NNRTI-based first-line regimen used in Mali is suboptimal for some patients. This study should be done regularly to inform clinical practice.
UR - http://www.scopus.com/inward/record.url?scp=84871898619&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84871898619&partnerID=8YFLogxK
U2 - 10.1089/aid.2012.0118
DO - 10.1089/aid.2012.0118
M3 - Article
C2 - 22823755
AN - SCOPUS:84871898619
VL - 29
SP - 182
EP - 186
JO - AIDS Research and Human Retroviruses
JF - AIDS Research and Human Retroviruses
SN - 0889-2229
IS - 1
ER -